Investors Bet on High-Growth Pharma Companies
While deal count is down across the board, a select crop of successful pharma businesses continues to trade for high multiples
Stay up to date on the latest in the middle market with Middle Market Growth’s timely and relevant analysis from editorial staff, guest contributors and industry leaders.